{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:08:10Z","timestamp":1792609690694,"version":"4.5.0"},"reference-count":13,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eptacog alfa and eptacog beta are recombinant factor VIIa (rFVIIa) agents approved for use in hemophilia A or B with inhibitors. Our institution converted from eptacog alfa to eptacog beta as the preferred rFVIIa product. The objective of this medication use evaluation was to review the utilization of both agents and cost savings associated with the conversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective chart review for all eptacog alfa and beta administrations from October 2023 through September 2024. We evaluated product selection and dosing as well as the occurrence of thrombosis, new bleeding events, or existing bleeding that required therapy escalation. Cost savings were estimated using wholesale acquisition costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 17 patients that required 27 admissions for rFVIIa (eptacog alfa: 3, 11.1% and eptacog beta: 21, 77.8%). Three administrations (11.1%) utilized both agents. Indications included bleeding in hemophilia patients (12, 44.4%), followed by peri-procedural management (9, 33.3%), cardiac surgery (3, 11.1%), and anticoagulation reversal for life-threatening bleeding (3, 11.1%). There were 21 administrations in which eptacog beta was exclusively used (bleeding in hemophilia A (9, 33.3%), peri-procedural management (7, 25.9%), cardiac surgery (2, 7.4%), and anticoagulation reversal (3, 11.1%)). There were no thrombotic events. There were 5 patients (18.5%) who required rFVIIa dose escalation and two (7.4%) who required re-initiation of rFVIIa. Cost avoidance was estimated at $554,400 over a 12-month period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We treated a small cohort of patients with eptacog beta without adverse outcomes. Other hospitals might evaluate their rFVIIa use and consider opportunities for substitution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296251405425","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:29:57Z","timestamp":1765470597000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6005-0738","authenticated-orcid":false,"given":"Alyssa R.","family":"George","sequence":"first","affiliation":[{"name":"Henry Ford Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-2354","authenticated-orcid":false,"given":"Katelyn W.","family":"Sylvester","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4942-6689","authenticated-orcid":false,"given":"Dareen M.","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabashni","family":"Reddy","sequence":"additional","affiliation":[{"name":"Mass General Brigham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-2637","authenticated-orcid":false,"given":"John R.","family":"Fanikos","sequence":"additional","affiliation":[{"name":"Vasculearn Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-7826","authenticated-orcid":false,"given":"Nathan T.","family":"Connell","sequence":"additional","affiliation":[{"name":"Department of Hematology, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"NovoSeven [prescribing information]. Novo Nordisk Inc. July 2014. Accessed July 3 2024. https:\/\/www.fda.gov\/media\/70442\/download."},{"key":"e_1_3_4_3_2","unstructured":"Sevenfact [prescribing information]. HEMA Biologics November 2022. Accessed July 3 2024. https:\/\/sevenfact.com\/Sevenfact_PI.pdf."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.09.008"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.15094"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa393"},{"key":"e_1_3_4_7_2","unstructured":"Lexicomp Online [database online]. Wolters Kluwer Clinical Drug Information Inc 2024. Accessed February 23 2024. https:\/\/www.wolterskluwer.com\/en\/solutions\/uptodate\/enterprise\/lexidrug."},{"key":"e_1_3_4_8_2","unstructured":"McKesson Connect. https:\/\/connect.mckesson.com\/portal\/. Accessed July 3 2024."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S284804"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13301"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14418"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M447"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000001079"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004411"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251405425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251405425","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251405425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:31Z","timestamp":1777385131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251405425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":13,"alternative-id":["10.1177\/10760296251405425"],"URL":"https:\/\/doi.org\/10.1177\/10760296251405425","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"10760296251405425"}}